Showing posts with label liver transplants. Show all posts
Showing posts with label liver transplants. Show all posts

Friday, August 15, 2008

A little Cuervo...


A little Cuervo Can Be Good for You

By Michael Leshinski

A little Cuervo in your life can actually help your liver instead of destroying it. No, I am not talking about the popular tequila maker, but rather about a molecular biologist who shares the same name. As reported by Wired magazine, Dr. Ana Cuervo is working on research that could possibly provide healthier livers to booze hounds in the future. Cuervo and her fellow researchers at Albert Einstein College of Medicine have been working with mice through genetic engineering. The altered mice are usually elderly, in mouse years, but have been altered so that their liver works as effectively as young mice (6 months old). The study focused on a protein found in the liver as well as other parts of the body. The protein collects cellular by-products, mainly appearing as damaged proteins, or garbage as they put it.

The group employs simple logic to back the research. If you take out the garbage properly, then the rest of the cell should work just fine. And it has been so far for these little furry test subjects. Besides the possibility for a healthier liver, the research could be breakthrough for Alzheimer’s disease, a disease also associated with the buildup of cellular by-products. But don’t start celebrating with the Cuervo shots just yet. The research being done is still in very early stages and the possible transformation into human medication has not even yet been thought discussed. Whether you’re a fan of consequence free alcohol consumption or someone who really cares about the advancement of research in these important issues, news can be welcomed by all.

Sunday, May 04, 2008

The God Squad Redux?

There has been a simple problem with organ transplants, for as long as it has been technologically possible to do so: there are never, ever enough organs. And that leads to the simple, painful, difficult question of how you decide who receives a organ, and who is consigned to death that could have been prevented. And perhaps most importantly, how do you make that decision ethically?

For better or worse, much of the debate on who gets to play god has centered in and around the medical facilities in Seattle. Almost everyone knows the history of Dr. Belding Scriber and the hemodialysis God Squad, with the now-infamous headline “They Decide Who Shall Live and Who Shall Die.” And their criteria for choosing who did receive dialysis is almost painful to consider these days: a married Christian white man with children? Worthy member of society, should be saved! Single convict? Let 'im die.

It's a well-known history, in bioethics and Seattle proper. So it was with some surprise that I read, in the morning's news cycle, that the University of Washington was back in the news with accusations that their transplant committee was playing god. Only this time, they're second-guessing other medical professionals in the process.

The situation itself is simple: a man in need of a liver transplant was prescribed medical marijuana use by his physician to control pain, alleviate nausea, and stimulate his appetite.

The marijuana use, according to a doctor at Harborview Medical Center, would prohibit his paperwork for transplanting being processed. He would have to abstain for six months - a ruling eventually dropped in favour of an offer to reconsider after completion of a 60 day substance abuse program. Sixty days that the patient didn't have. On appeal, the University of Washington Medical Center agreed to consider the case again, and a week ago rejected the man from transplant consideration for a second time.

Medical use of marijuana was approved by Washington voters back in 1998, yet use of illicit substances is often grounds for rejecting someone's place on the transplant list. UNOS leaves the specific criteria to each individual hospital, and the information coming out of Seattle seems to suggest that UW's policy is not automatic rejection, but instructions to abstain for six months to then be reconsidered. (And of course, the medical center itself is not commenting on this case, save to say a range of factors play into every decision made regarding transplant cases).

The problem with this is hopefully simple: if a patient is using marijuana under medical supervision, why should it be considered problematic? Or any more problematic than the use of any other addictive substance (such as most pain medications).

The other problem is less simple. Physicians trying to do right by their patients, trying to alleviate pain and suffering (something that is often difficult to even motivate physicians to do, as continued coverage of the dearth of chronic pain management indicates), are inadvertently creating a situation where their patients are actually being denied further medical treatment based on their current treatment.

Peggy Stewart, a clinical social worker in the UCLA liver transplant center, has a simple solution: create a national eligibility criteria, so that everyone is on the same page, and aware of what will and will not increase their chances at actually being placed on the list.

Or, if I may be so bold as to point out the obvious, don't penalize a patient for following the medical advice of a fully licensed physician.
-Kelly Hills

Saturday, December 22, 2007

In the Case of Nataline Sarkisyan

My immediate reaction when first learning of this case, was one of outrage. How dare yet another bean-counting, uncaring, bottom-line thinking insurer, whose job it is to provide health coverage to paying policy-holders, how dare they allow a 17-year old child to die because of petty haggling over approval of a life-saving transplant procedure? How dare they? Particularly given the already tarnished image faced by most of the industry heavy-weights.

Yet, here we are, weighing in on yet another case that at first blush looks like the usual big-guy insurance-giant bullying the little-guy. But is it?
Here is the breakdown:
  • Nataline Sarkisyan, 17-year leukemia patient dies after being removed from life support following complications developed after a bone marrow transplant from her brother the day before Thanksgiving. The complications caused Nataline's liver to fail, placing her in a vegetative state.
  • Nataline's doctors at the University of California, Los Angeles Medical Center, appealed to the Sarkisyan's insurer, Cigna Corp., to reconsider an initial refusal of a liver transplant, which doctors said was crucial to her survival. Cigna initially refused to authorize the procedure, calling it experimental.
  • Cigna later rescinds the earlier decision, agreeing to the transplant in an 11th hour change of heart.
  • Nataline dies within an hour of being removed from life support.
Nataline's family has promptly filed suit against Cigna, retaining the legal services of Mark Geragos (remember him from the Michael Jackson and Scott Peterson trials?), who promptly blamed the insurer for Nataline's death. Geragos has asked the California District Attorney's office to press murder or manslaughter charges against Cigna, claiming, the insurer "maliciously killed" her because it didn't want to pay for her transplant and aftercare.

At issue is whether the procedure would indeed have saved her life. Doctors in the case stated the survival rate for patients in similar situations is six months at 65 percent. A complicated case.
Access the article here